Shares of Johnson & Johnson (NYSE:JNJ) have earned a consensus rating of “Hold” from the twenty-three brokerages that are presently covering the firm. Two analysts have rated the stock with a sell rating, twelve have given a hold rating and nine have issued a buy rating on the company. The average 12 month price target among analysts that have covered the stock in the last year is $120.35.

JNJ has been the subject of a number of analyst reports. Argus reiterated a “buy” rating and issued a $145.00 price target on shares of Johnson & Johnson in a research note on Friday, October 21st. Zacks Investment Research lowered Johnson & Johnson from a “hold” rating to a “sell” rating in a research note on Wednesday, September 28th. Leerink Swann reiterated a “buy” rating on shares of Johnson & Johnson in a research note on Sunday, September 11th. BTIG Research reiterated a “neutral” rating on shares of Johnson & Johnson in a research note on Thursday, August 25th. Finally, Vetr upgraded Johnson & Johnson from a “hold” rating to a “buy” rating and set a $124.21 price target for the company in a research note on Monday, August 22nd.

Shares of Johnson & Johnson (NYSE:JNJ) opened at 116.57 on Tuesday. Johnson & Johnson has a 1-year low of $94.28 and a 1-year high of $126.07. The company has a market cap of $317.13 billion, a price-to-earnings ratio of 20.46 and a beta of 0.75. The stock has a 50 day moving average price of $116.90 and a 200-day moving average price of $118.28.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Tuesday, October 18th. The company reported $1.68 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.66 by $0.02. Johnson & Johnson had a return on equity of 25.30% and a net margin of 22.03%. The business earned $17.80 billion during the quarter, compared to analyst estimates of $17.71 billion. During the same quarter in the prior year, the business posted $1.49 EPS. Johnson & Johnson’s revenue for the quarter was up 4.2% compared to the same quarter last year. Equities research analysts forecast that Johnson & Johnson will post $6.72 earnings per share for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 6th. Investors of record on Tuesday, November 22nd will be issued a dividend of $0.80 per share. This represents a $3.20 annualized dividend and a yield of 2.75%. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $0.29. The ex-dividend date of this dividend is Friday, November 18th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 56.64%.

In other Johnson & Johnson news, Director Charles Prince acquired 875 shares of the business’s stock in a transaction that occurred on Friday, October 21st. The shares were bought at an average cost of $114.11 per share, with a total value of $99,846.25. Following the completion of the acquisition, the director now directly owns 26,520 shares in the company, valued at approximately $3,026,197.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 0.11% of the company’s stock.

A number of institutional investors have recently modified their holdings of the stock. Colony Group LLC raised its position in shares of Johnson & Johnson by 3.0% in the third quarter. Colony Group LLC now owns 16,282 shares of the company’s stock valued at $1,923,000 after buying an additional 480 shares during the last quarter. Price T Rowe Associates Inc. MD raised its position in shares of Johnson & Johnson by 1.0% in the third quarter. Price T Rowe Associates Inc. MD now owns 17,297,558 shares of the company’s stock valued at $2,043,360,000 after buying an additional 171,695 shares during the last quarter. Garde Capital Inc. raised its position in shares of Johnson & Johnson by 254.5% in the third quarter. Garde Capital Inc. now owns 6,821 shares of the company’s stock valued at $637,000 after buying an additional 4,897 shares during the last quarter. Altfest L J & Co. Inc. raised its position in shares of Johnson & Johnson by 6.2% in the third quarter. Altfest L J & Co. Inc. now owns 21,230 shares of the company’s stock valued at $2,508,000 after buying an additional 1,245 shares during the last quarter. Finally, High Falls Advisors Inc raised its position in shares of Johnson & Johnson by 3.8% in the third quarter. High Falls Advisors Inc now owns 7,600 shares of the company’s stock valued at $898,000 after buying an additional 275 shares during the last quarter. 65.35% of the stock is currently owned by institutional investors.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company’s segments include Consumer, Pharmaceutical and Medical Devices. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women’s health and wound care markets.

5 Day Chart for NYSE:JNJ

Receive News & Stock Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related stocks with our FREE daily email newsletter.